Efficacy and Safety of Nitazoxanide in Addition to Standard of Care for the Treatment of Severe Acute Respiratory Illness
Author:
Gamiño-Arroyo Ana E1, Guerrero M Lourdes2, McCarthy Sean3, Ramírez-Venegas Alejandra4, Llamosas-Gallardo Beatriz5, Galindo-Fraga Arturo2, Moreno-Espinosa Sarbelio1, Roldán-Aragón Yuri6, Araujo-Meléndez Javier7, Hunsberger Sally8, Ibarra-González Violeta2, Martínez-López Julia2, García-Andrade Luis A2, Kapushoc Heather3, Holley H Preston8, Smolskis Mary C8, Ruiz-Palacios Guillermo M29, Beigel John H10ORCID, , Guerrero M Lourdes, Gamiño-Arroyo Ana E, Ramírez-Venegas Alejandra, Bautista Nora, Nolasco-Reza Angélica, Llamosas-Gallardo Beatriz, Ortiz-Hernández Ana A, Andrade-Platas Diana, Estevez-Jimenez Juliana, Galindo-Fraga Arturo, Roa-Martínez Bricia, Cruz-Gaona Itzel, Aguilar-Cruz Diana, Moreno-Espinosa Sarbelio, González-Matus Mónica, Mendoza-Garcés Luis, Araujo-Meléndez Javier, Perea-Guzmán Norma, Sandoval-Gutiérrez Ana, Hernández-Ramírez Daniel, Hernández-Sánchez Pedro Gerardo, Roldán-Aragón Yuri A, Davila-Cruz Alejandra N, Ibarra-González Violeta, Martínez-López Julia, García-Andrade Luis A, Ruiz-Palacios Guillermo M, Beigel John H, Smolskis Mary, Hunsberger Sally, Sean McCarthy H, Grue Louis, Burge Gregory, Cox Roxanne, Holley Preston, Cristillo Anthony, Nahed Nasreen, López Wendolyne, Becerril-Ruiz Eli Xchel, Quidgley Peter, Arroyo-Figueroa Hugo
Affiliation:
1. Hospital Infantil de México “Dr Federico Gómez, Mexico City, Mexico 2. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico 3. Social and Scientific Systems, Inc, Silver Spring, Maryland 4. Instituto Nacional de Enfermedades Respiratorias, Mexico City 5. Instituto Nacional de Pediatría, Mexico City 6. Hospital General “Dr Aurelio Valdivieso,” Oaxaca, Mexico 7. Hospital Central “Dr Ignacio Morones-Prieto,” San Luis Potosi, Mexico 8. National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 9. Comisión Coordinadora de los Institutos Nacionales de Salud y Hospitales de Alta Especialidad, Secretaría de Salud, Mexico City 10. Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Maryland
Abstract
Abstract
Background
Effective therapeutics for respiratory viruses are needed. Early data suggest that nitazoxanide (NTZ) may be beneficial for treating acute respiratory viral illness.
Methods
From March 2014 through March 2017, a double-blind, placebo-controlled trial was conducted in 260 participants ≥1 year old hospitalized with influenza-like illness at 6 hospitals in Mexico. Participants were randomized 1:1 to NTZ (age ≥12 years, 600 mg twice daily; age 4–11 years and 1–3 years, 200 or 100 mg twice daily, respectively) or placebo for 5 days in addition to standard of care. The primary endpoint was time from first dose to hospital discharge. Influenza reverse-transcription polymerase chain reaction and Respifinder 22 multiplex test were used for virus detection.
Results
Of 260 participants enrolled, 257 were randomized and took at least 1 dose of study treatment (intention-to-treat population): 130 in the NTZ group and 127 in the placebo group. The Kaplan-Meier estimate of the median duration of hospitalization was 6.5 (interquartile range [IQR], 4.0–9.0) days in the NTZ group vs 7.0 (IQR, 4.0–9.0) days in the placebo group (P = .56). Duration of hospitalization between the 2 treatments was similar in children (P = .29) and adults (P = .62), influenza A and B (P = .32), and other respiratory viruses. Seven (5.4%) and 6 (4.7%) participants in the NTZ and placebo groups, respectively, reported serious adverse events.
Conclusions
Treatment with NTZ did not reduce the duration of hospital stay in severe influenza-like illness. Further analyses based on age and evaluations by virus did not reveal any subgroups that appeared to benefit from NTZ.
Clinical Trials Registration
NCT02057757.
Funder
National Institute of Allergy and Infectious Diseases Consejo Nacional de Ciencia y Tecnología National Cancer Institute National Institutes of Health
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Microbiology (medical)
Reference21 articles.
1. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study;Murray;Lancet,1997 2. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013;Global Burden of Disease Study 2013 Collaborators;Lancet,2015 3. School absenteeism among school-age children with medically attended acute viral respiratory illness during three influenza seasons, 2012–2013 through 2014–2015;McLean;Influenza Other Respir Viruses,2017 4. Illness severity and work productivity loss amoung working adults with medically attended acute respiratory illnesses: US Influenza Vaccine Effectiveness Network 2012–2013;Petrie;Clin Infect Dis,2016 5. Clinical characteristics and outcomes of influenza and other influenza-like illnesses in Mexico City;Galindo-Fraga;Int J Infect Dis,2013
Cited by
44 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|